COMBINATION THERAPY WITH T4 AND T3 IN HYPOTHYROIDISM: INDICATIONS, EFFECTIVENESS, AND CLINICAL DEBATES

B.B. Begmatov[1], Yu.M. O'rmanova[2], D.U. Muhammadumarova[3]
Tashkent State Medical University, Alfraganus University[1,2,3]
https://doi.org/10.5281/zenodo.17019750

Abstract. *Hypothyroidism is traditionally managed with levothyroxine (L-T4) monotherapy, aiming to restore serum thyrotropin (TSH) to the reference range [1]. However, a subset of patients continues to experience symptoms despite biochemical normalization [2,3]. Combination therapy with L-T4 and liothyronine (L-T3) has emerged as a potential strategy to address residual symptoms by more closely mimicking physiological thyroid hormone secretion [4]. This review evaluates the current evidence on indications, efficacy, and controversies surrounding combination therapy. Mechanistic insights into T4-to-T3 conversion, deiodinase polymorphisms, and tissue-specific thyroid hormone regulation are discussed [5,9]. Evidence suggests that while most patients achieve adequate outcomes on L-T4 alone, carefully selected individuals may benefit from combined therapy [2,3,6]. However, inconsistent clinical trial results and uncertainties regarding optimal dosing remain key barriers to widespread adoption [4,7,8]. Further high-quality, long-term studies are needed to refine patient selection and assess long-term safety [1,8].*

Keywords: *hypothyroidism, levothyroxine, liothyronine, T4/T3 combination therapy, deiodinase, personalized medicine.*

1. Introduction

Hypothyroidism is a prevalent endocrine disorder characterized by insufficient thyroid hormone production or action. The most common cause in iodine-sufficient regions is chronic autoimmune thyroiditis (Hashimoto's disease), while other causes include thyroidectomy, radioiodine therapy, and certain medications [1]. Standard therapy involves oral levothyroxine (L-T4), a synthetic form of thyroxine, which is converted peripherally into the active triiodothyronine (T3) by deiodinase enzymes [9].

Although L-T4 monotherapy effectively normalizes serum TSH in the majority of patients, up to 10–15% continue to report persistent symptoms such as fatigue, cognitive slowing, mood disturbances, and weight gain [3,10]. These residual complaints have driven interest in combination therapy with L-T4 and L-T3, intended to replicate the physiological thyroid secretion ratio of approximately 14:1 (T4:T3) and restore optimal tissue thyroid hormone action [2,4,8].

This article examines the mechanistic rationale, clinical evidence, and controversies regarding combination therapy, with an emphasis on patient selection and practical considerations.

2. Materials and Methods

This review synthesizes evidence from randomized controlled trials (RCTs), observational studies, meta-analyses, and authoritative clinical guidelines published between 2000 and 2024 [1–4,6–8]. Sources were identified through PubMed and Scopus searches using the keywords "T4 T3 combination therapy," "hypothyroidism," "deiodinase polymorphism," and "levothyroxine resistance." Only studies involving adult patients with primary hypothyroidism were included.

Data were extracted regarding dosing strategies, clinical outcomes, biochemical changes, safety profiles, and patient-reported measures [5,9].

Mechanistic information was compiled from basic science literature on thyroid hormone metabolism, including deiodinase activity, thyroid hormone transporters, and nuclear receptor regulation.

3. Results

3.1 Mechanistic Rationale

In euthyroid physiology, the thyroid gland secretes both T4 and T3, with T3 being the biologically active hormone that binds thyroid hormone receptors in the nucleus, regulating gene transcription [5]. Peripheral conversion of T4 to T3 is mediated primarily by type 1 and type 2 deiodinases (D1, D2). Genetic polymorphisms in the DIO2 gene, such as Thr92Ala, have been associated with altered enzyme activity and impaired local T3 generation in specific tissues, potentially contributing to persistent symptoms despite normal serum TSH [6].

Combination therapy directly provides exogenous T3, bypassing potential conversion inefficiencies [2,3]. Theoretically, this can restore physiological fluctuations in serum T3 levels and improve tissue-specific thyroid hormone action, particularly in the brain and skeletal muscle [5,9].

3.2 Clinical Evidence

Clinical trials have yielded mixed results. Several small RCTs demonstrated modest improvements in mood, cognitive performance, and patient preference with combination therapy [2,3], while others showed no significant benefit over L-T4 alone. A consistent observation is that some patients express a subjective preference for combination therapy, even in the absence of objective biochemical or neuropsychological improvements [2,3,6,10].

Meta-analyses indicate no universal superiority of combination therapy but highlight that heterogeneity in dosing regimens, treatment duration, and outcome measures complicates interpretation [4]. Observational studies suggest that careful patient selection—considering persistent symptoms, exclusion of comorbidities, and potential DIO2 polymorphisms—may identify those more likely to respond [6,8].

Component	Role	Clinical relevance
T4 (levothyroxine)	Circulating prohormone; main blood reservoir for thyroid hormone	Standard replacement; dose titrated to normalize TSH
T3 (liothyronine)	Active hormone that binds nuclear TRs and rapidly modulates gene transcription	Supplementation can increase tissue T3 but may cause peaks/troughs
Deiodinases (D1, D2)	Enzymes that convert T4 → T3 (or produce rT3) in tissue-specific manner	Polymorphisms (e.g., DIO2 Thr92Ala) can reduce local T3 production → candidate for combo therapy
Thyroid hormone receptors (TR*α*, TRβ)	Nuclear receptors mediating genomic effects; different isoforms in tissues	Tissue-specific responses depend on receptor distribution
Transporters (MCT8, MCT10, OATP1C1)	Shuttle thyroid hormones across cell membranes	Transporter defects (rare) alter intracellular availability

Study (Author, Year)	N	Duration	Design	Key numeric findings
Saravanan et al., 2005	697	Up to 12 months	Parallel	TSH ↑132%, fT4 ↓35% (P<0.001); GHQ-12 OR 0.61 (P=0.01)
Escobar-Morreale et al., 2005	28	8 weeks/period	Crossover	fT4 ↓ 3.9 pmol/L (95% CI 2.5–5.3), P<0.05
Meta-analysis (2024)	~15 studies	Variable	Meta-analysis	Free T4 MD −0.34 (95% CI −0.47–−0.20), p<0.00001; Total T3 MD +29.82 (95% CI 22.4–37.25), p<0.00001
Panicker et al., 2009	Cohort	—	Observational	Thr92Ala variant: GHQ improvement +2.3 at 3 mo; +1.4 at 12 mo
Celi et al., 2011	14	Crossover	Crossover	T3 peaks AUC ↑; variable metabolic effects

3.3 Dosing Strategies and Challenges

Optimal T4:T3 ratios for replacement remain uncertain. The physiological secretion ratio is around 14:1, but oral dosing must consider T3's shorter half-life and higher potency [8]. Many protocols reduce the L-T4 dose by 50 µg for each 10 µg of added L-T3. Twice-daily or slow-release T3 formulations are preferred to minimize peaks and troughs in serum T3 [7].

Challenges include avoiding T3-induced thyrotoxicosis, ensuring adherence, and balancing symptom relief with biochemical stability [8].

4. Discussion

Combination therapy remains a subject of clinical debate. While guidelines from the American Thyroid Association (ATA) and European Thyroid Association (ETA) endorse L-T4 as first-line treatment [1], they allow a trial of combination therapy in selected patients under specialist supervision [8].

Potential benefits include improved quality of life for a subset of patients [2,3,10], better alignment with physiological hormone ratios [5,8], and accommodation for genetic or enzymatic differences in hormone metabolism. Limitations include inconsistent evidence [4,7], potential cardiovascular risks from T3 excess, and the lack of standardized dosing protocols [1].

The debate underscores the need for personalized medicine in hypothyroidism management [8]. Future studies should explore biomarkers (e.g., deiodinase activity, genetic profiling) to guide therapy, as well as long-term safety of sustained combination therapy [6,8].

5. Conclusion

L-T4 monotherapy remains the gold standard for hypothyroidism treatment [1]. However, combination therapy with L-T4 and L-T3 may benefit selected patients with persistent symptoms despite optimized L-T4 dosing [2,3,6,10]. Mechanistic insights into thyroid hormone metabolism support its use in individuals with impaired peripheral T4-to-T3 conversion [5,9]. Clinical implementation requires careful dosing, monitoring, and patient counseling [8]. Ongoing research

should aim to define precise selection criteria, refine dosing strategies, and evaluate long-term outcomes [4,7].

REFERENCES

1. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670–1751.
2. Escobar-Morreale HF, Botella-Carretero JI, Gomez-Bueno M, et al. Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med. 2005;142(6):412–424.
3. Saravanan P, Simmons DJ, Greenwood R, et al. Partial substitution of thyroxine (T4) with triiodothyronine in patients on thyroxine replacement therapy: results of a large community-based randomized controlled trial. J Clin Endocrinol Metab. 2005;90(2):805–812.
4. Grozinsky-Glasberg S, Fraser A, Nahshoni E, et al. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2006;91(7):2592–2599.
5. Celi FS, Zemskova M, Linderman JD, et al. Metabolic effects of liothyronine therapy in hypothyroid patients: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. J Clin Endocrinol Metab. 2011;96(11):3466–3474.
6. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009;94(5):1623–1629.
7. Hoang TD, Olsen CH, Mai VQ, et al. Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab. 2013;98(5):1982–1990.
8. Wiersinga WM. Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism. Nat Rev Endocrinol. 2014;10(3):164–174.
9. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006;116(10):2571–2579.
10. Mitchell AL, Hegedüs L, Žarković M, et al. Patient satisfaction and quality of life in hypothyroidism: an online survey by the British Thyroid Foundation. Clin Endocrinol (Oxf). 2021;94(3):513–520.